Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) shares crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.14 and traded as high as $2.86. Microbot Medical shares last traded at $2.84, with a volume of 3,286,792 shares trading hands.
Analysts Set New Price Targets
Several analysts have recently weighed in on the company. Wall Street Zen upgraded Microbot Medical from a "sell" rating to a "hold" rating in a research note on Saturday, June 14th. HC Wainwright reissued a "buy" rating and issued a $9.00 price objective on shares of Microbot Medical in a report on Thursday, April 10th.
Check Out Our Latest Stock Report on MBOT
Microbot Medical Stock Down 1.2%
The firm has a market cap of $106.78 million, a P/E ratio of -4.50 and a beta of 1.13. The firm's 50-day moving average price is $2.57 and its 200 day moving average price is $2.15.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 21st. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.07. On average, equities analysts predict that Microbot Medical Inc. will post -0.71 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC bought a new stake in shares of Microbot Medical in the 4th quarter worth approximately $118,000. Geode Capital Management LLC raised its holdings in shares of Microbot Medical by 7.9% in the fourth quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock valued at $160,000 after buying an additional 10,442 shares during the last quarter. Goldman Sachs Group Inc. bought a new position in Microbot Medical in the 1st quarter worth approximately $57,000. Lazari Capital Management Inc. acquired a new stake in shares of Microbot Medical in the 2nd quarter valued at $54,000. Finally, Beacon Capital Management LLC lifted its stake in shares of Microbot Medical by 166.7% during the second quarter. Beacon Capital Management LLC now owns 16,000 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 10,000 shares during the period. Institutional investors own 16.30% of the company's stock.
Microbot Medical Company Profile
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
Read More
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access